Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Centre Hospitalier Universitaire Vaudois
Massachusetts General Hospital
University of Maryland, Baltimore
Shenzhen BinDeBio Ltd.